From GlobeNewswire: 2025-04-28 01:00:00

The Committee for Medicinal Products for Human Use (CHMP) has recommended European Commission (EC) approval of VYVGART® 1000mg for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). VYVGART is the first targeted IgG Fc-antibody fragment for CIDP, offering a novel mechanism of action after 30 years. The decision by the EC is expected within approximately two months. The positive recommendation is based on the results of the ADHERE clinical trial, the largest study of CIDP patients to date, which showed significant clinical improvement and functional benefits for patients. The decision will apply to all 27 European Union Member States, as well as Iceland, Norway, and Liechtenstein.



Read more at GlobeNewswire: argenx Announces Positive CHMP Opinion for VYVGART